(Q42642151)

4 November 2017

title

Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study (English)

1 reference

4 November 2017

Mark S Kipnes

1

1 reference

4 November 2017

Eli M Roth

2

1 reference

4 November 2017

James M Rhyne

3

1 reference

4 November 2017

Carolyn M Setze

4

1 reference

4 November 2017

Aditya Lele

5

1 reference

4 November 2017

Maureen T Kelly

6

1 reference

4 November 2017

Darryl J Sleep

7

1 reference

4 November 2017

James C Stolzenbach

8

1 reference

4 November 2017

publication date

1 January 2010

1 reference

Clinical Drug Investigation

4 November 2017

published in

1 reference

4 November 2017

volume

30

1 reference

4 November 2017

issue

1

1 reference

4 November 2017

page(s)

51-61

1 reference

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

4 November 2017

cites work

1 reference

12 December 2020

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia

1 reference

12 December 2020

Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia

1 reference

12 December 2020

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

1 reference

12 December 2020

Triglycerides and the Risk of Coronary Heart Disease

1 reference

12 December 2020

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study

1 reference

12 December 2020

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

1 reference

12 December 2020

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

12 December 2020

Risk of cardiovascular events in patients at optimal values for combined lipid parameters

1 reference

12 December 2020

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

1 reference

12 December 2020

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study

1 reference

12 December 2020

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

1 reference

12 December 2020

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

1 reference

12 December 2020

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

1 reference

12 December 2020

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies

1 reference

12 December 2020

Standards of medical care in diabetes--2009.

1 reference

12 December 2020

Deaths: final data for 2004.

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

10.2165/11319800-000000000-00000

Identifiers

DOI

1 reference

4 November 2017

1 reference